BioCryst Announces Departure of Dr. Helen Thackray
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Dr. Helen Thackray, Chief Research and Development Officer, will depart the company on September 1, 2025, transitioning to an advisory role through year-end. Dr. Thackray, who joined as a board member in 2019 and became R&D chief in 2021, was a finalist in the recent CEO succession process.
Under her leadership, BioCryst achieved significant milestones, including launching the KLK5 inhibitor BCX17725 for Netherton syndrome, advancing the avoralstat program for diabetic macular edema, and bringing the ORLADEYO pediatric program close to market approval. Dr. Thackray is departing to pursue a chief executive leadership opportunity elsewhere.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato che la Dott.ssa Helen Thackray, Chief Research and Development Officer, lascerà l'azienda il 1° settembre 2025, passando a un ruolo di consulente fino a fine anno. La Dott.ssa Thackray, entrata nel consiglio di amministrazione nel 2019 e nominata responsabile R&S nel 2021, è stata finalista nel recente processo di successione per il CEO.
Sotto la sua guida BioCryst ha raggiunto importanti traguardi, tra cui il lancio del inibitore KLK5 BCX17725 per la Netherton syndrome, l'avanzamento del programma avoralstat per l'edema maculare diabetico e l'avvicinamento del programma pediatrico ORLADEYO all'approvazione di mercato. La Dott.ssa Thackray si allontana per cogliere un'opportunità come amministratore delegato in un'altra società.
BioCryst Pharmaceuticals (Nasdaq: BCRX) anunció que la Dra. Helen Thackray, Chief Research and Development Officer, dejará la compañía el 1 de septiembre de 2025, y pasará a una función de asesoría hasta final de año. La Dra. Thackray, que se incorporó como miembro de la junta en 2019 y se convirtió en responsable de I+D en 2021, fue finalista en el reciente proceso de sucesión del CEO.
Bajo su liderazgo BioCryst consiguió hitos relevantes, entre ellos el lanzamiento del inhibidor KLK5 BCX17725 para Netherton syndrome, el avance del programa avoralstat para edema macular diabético y el acercamiento del programa pediátrico ORLADEYO a la aprobación de mercado. La Dra. Thackray se marcha para asumir una oportunidad como directora ejecutiva en otra compañía.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 Dr. Helen Thackray 수석 연구개발 책임자가 2025년 9월 1일부로 회사를 떠나 연말까지 자문 역할을 맡을 예정이라고 발표했다. Thackray 박사는 2019년 이사회 멤버로 합류했으며 2021년 R&D 책임자로 선임되었고, 최근 CEO 승계 과정에서 최종 후보 중 한 명이었다.
그녀의 리더십 하에 BioCryst는 중요한 성과를 거두었으며, 여기에는 Netherton syndrome 치료를 위한 KLK5 억제제 BCX17725의 출시, 당뇨성 황반부종을 위한 avoralstat 프로그램의 진전, 그리고 ORLADEYO 소아 프로그램의 시판 승인 근접 등이 포함된다. Thackray 박사는 다른 곳에서 최고경영자(CEO) 역할 기회를 추구하기 위해 회사를 떠난다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé que Dr. Helen Thackray, Chief Research and Development Officer, quittera la société le 1er septembre 2025, en passant à un rôle de conseillère jusqu'à la fin de l'année. Dr. Thackray a rejoint le conseil d'administration en 2019 et est devenue responsable R&D en 2021 ; elle a été finaliste lors du récent processus de succession du PDG.
Sous sa direction, BioCryst a atteint des étapes importantes, notamment le lancement de l'inhibiteur KLK5 BCX17725 pour la Netherton syndrome, l'avancement du programme avoralstat pour l'œdème maculaire diabétique et la mise en proximité de l'programme pédiatrique ORLADEYO avec l'approbation commerciale. Dr. Thackray part pour saisir une opportunité de direction générale dans une autre entreprise.
BioCryst Pharmaceuticals (Nasdaq: BCRX) gab bekannt, dass Dr. Helen Thackray, Chief Research and Development Officer, das Unternehmen am 1. September 2025 verlassen und bis zum Jahresende in eine beratende Funktion wechseln wird. Dr. Thackray trat 2019 als Mitglied des Verwaltungsrats bei und wurde 2021 Leiterin der F&E; sie war Finalistin im jüngsten Nachfolgeprozess für den CEO.
Unter ihrer Führung erzielte BioCryst bedeutende Erfolge, darunter die Einführung des KLK5-Inhibitors BCX17725 für Netherton syndrome, die Weiterentwicklung des avoralstat-Programms für diabetisches Makulaödem und das Heranführen des pädriatrischen Programms ORLADEYO an die Marktzulassung. Dr. Thackray verlässt das Unternehmen, um eine Position als Chief Executive in einem anderen Unternehmen wahrzunehmen.
- Development of novel KLK5 inhibitor BCX17725 for Netherton syndrome
- Advancement of avoralstat program for diabetic macular edema from discovery to clinic
- ORLADEYO pediatric program nearing market approval
- Loss of key executive who led multiple successful R&D initiatives
- Potential disruption in R&D leadership during critical development phases
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Dr. Thackray first joined the company as a member of the board of directors in 2019 and was appointed chief research and development officer in 2021. She was a finalist internal candidate considered by the board of directors in the chief executive officer succession process. Following the recent completion of that process, she has decided to leave the company to pursue another chief executive leadership opportunity.
“I am deeply grateful to Helen for the contributions she has made to BioCryst, including launching a new protein therapeutics platform capability with our novel KLK5 inhibitor, BCX17725 for Netherton syndrome, driving our avoralstat program for diabetic macular edema from discovery into the clinic and bringing our ORLADEYO pediatric program to the brink of market approval. I am excited for her as she seeks her next role as a leader in our industry,” said Jon Stonehouse, chief executive officer of BioCryst.
“I applaud the value BioCryst has delivered to individuals living with HAE in the last five years and am proud to have contributed to this with the potential upcoming addition of oral prophylaxis for children with HAE. I am grateful to my colleagues for their partnership and dedication to pursue better options for patients with rare diseases, and I will always count myself as part of the BioCryst family,” Thackray said.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance, achievements, and expectations regarding BioCryst’s pipeline. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; and BioCryst’s ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
When is Dr. Helen Thackray leaving BioCryst (BCRX)?
What major programs did Dr. Thackray oversee at BioCryst (BCRX)?
Why is Dr. Thackray leaving BioCryst Pharmaceuticals?
What positions did Dr. Thackray hold at BioCryst (BCRX)?
